EMGALITY

This brand name is authorized in Austria, Australia, Brazil, Canada, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, New Zealand, Poland, Romania, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug EMGALITY contains one active pharmaceutical ingredient (API):

1 Galcanezumab
UNII 55KHL3P693 - GALCANEZUMAB

Galcanezumab is a humanised IgG4 monoclonal antibody that binds calcitonin gene-related peptide (CGRP) thus preventing its biological activity. Elevated blood concentrations of CGRP have been associated with migraine attacks.

Read about Galcanezumab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
EMGALITY Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N02CD02 N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists
Discover more medicines within N02CD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 12469G, 12478R
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 507620030020707, 507620040020807, 507620040020907, 507620040021007, 507620040021107, 507620040021207, 507620040021307
Country: CA Health Products and Food Branch Identifier(s): 02491060, 02491087, 02505134
Country: EE Ravimiamet Identifier(s): 1782918, 1782929, 1808513, 1819065, 1819076, 1819087
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1181330001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 468840
Country: FR Base de données publique des médicaments Identifier(s): 69972332
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 374998
Country: HK Department of Health Drug Office Identifier(s): 66579, 66580
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 8741
Country: JP 医薬品医療機器総合機構 Identifier(s): 1190404G1020, 1190404G2026
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1086592, 1086593, 1086594, 1086595, 1087097, 1087098
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 20981, 20982
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100413118
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W67371001, W67371002, W67371005
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699673954714, 8699673954721, 8699673954738, 8699673954851
Country: US FDA, National Drug Code Identifier(s): 0002-1436, 0002-2377, 0002-3115
Country: ZA Health Products Regulatory Authority Identifier(s): 54/30.1/0062

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.